MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
40.48
-0.52
-1.26%
After Hours: 39.69 -0.79 -1.95% 19:51 11/13 EST
OPEN
40.89
PREV CLOSE
41.00
HIGH
41.20
LOW
39.84
VOLUME
607.67K
TURNOVER
--
52 WEEK HIGH
72.66
52 WEEK LOW
33.38
MARKET CAP
3.98B
P/E (TTM)
-8.6064
1D
5D
1M
3M
1Y
5Y
1D
Xenon Pharmaceuticals Earnings Call Signals Broad Pipeline Momentum
TipRanks · 3h ago
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Veeva Systems (VEEV) and Liquidia Technologies (LQDA)
TipRanks · 3d ago
Xenon Pharmaceuticals reports Q3 EPS ($1.11), consensus ($1.14)
TipRanks · 4d ago
Xenon: Undervalued Ahead of Azetukalner’s FDA Decision, with Pipeline and Liquidity Supporting Upside
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Xenon (XENE) and Perspective Therapeutics (CATX)
TipRanks · 4d ago
Needham Keeps Their Buy Rating on Xenon (XENE)
TipRanks · 4d ago
Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2
NASDAQ · 4d ago
Analyst Reiterates Buy on Azetukalner’s Clinical Promise, Maintains $74 Price Target
TipRanks · 4d ago
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.